Trial · Interventional

RecruitingPhase 2Registry data

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

Short name ESCALATE

NCTNCT06225284Other id202309050MIPB

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Recruiting
Phase: Phase 2
Enrollment: 124 participants (estimated)
Sponsor: National Taiwan University Hospital · Other
Design: Randomized · Open label (no masking)
Countries: 1 country
Taiwan
Start: 22 Aug 2024
Primary completion: Dec 2026 (estimated)
Completion: Dec 2030 (estimated)
First posted: 25 Jan 2024
Last update posted: 29 Apr 2025
Conditions: Triple Negative Breast Cancer · Premenopausal Breast Cancer

Timeline

1 trial · 1 ongoing

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2024202620282030

Ph 2
ESCALATE
NCT06225284
22 Aug 2024 to est. Dec 2030

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Breast cancer (BC), especially premenopausal, is emerging rapidly in East Asia in recent 20 years. Half of the breast cancer patients in Asia are younger than 50 years of age. In general, younger or premenopausal patients are associated with poorer prognosis. Premenopausal patients have higher estrogen levels than those in older (postmenopausal) patients. Estrogen is known to suppress anti-tumor T cell response and leading to tumor progression in different animal models (Clin Cancer Res 2016 22:6204), including lung cancer, melanoma, ovarian cancer. One of the mechanisms that contributes to estrogen's suppression of T cell function is via the mobilization of myeloid-derived suppressor cells (MDSC). Targeting ER signaling with hormonal therapy can abolish MDSC mobilization, and sensitize tumor cells to antigen specific T cell or NK cell killing (Cancer Discovery 2018 7:72 2017). These study results further support the hypothesis that, E2 is associated with immunosuppressive effect, and may contribute to the suppression of immune surveillance in young female breast cancer patients. These results suggest that E2 may suppress anti-tumor immunity, and E2 reduction improve the anti-tumor immunity. In our preliminary works, the investigators found higher dose (equivalent to premenopausal women serum level) of E2 suppressed T cell activities, while lower dose E2 (postmenopausal serum level) activated T cell activity. The investigators have investigated the combination of anti-PD1 antibody and GnRH agonist plus exemestane (an aromatase inhibitor which will block the production of E2 from adipose tissue) in ER positive premenopausal breast cancer patient refractory to prior endocrine therapy in metastatic setting. The response rate was 38.4%, and median progression-free survival (PFS) was 10.2 months. This outstanding result were presented in AACR 2021 oral session (Cancer Res 2021 81:13\_Supplement, CT028). On the other hand, progesterone is also well known for its anti-inflammation and immune tolerance activity. This possibly makes estrogen reduction treatments, such as gonadotropin-releasing hormone agonist (GnRH agonist), an important partner in augmenting neoadjuvant therapy for patients with premenopausal breast cancer. For triple negative breast cancer (TNBC), endocrine therapy has no anti-tumor effect. On the other hand, the use of GnRH agonist has been tested for the protection of ovary function of young female while receiving adjuvant chemotherapy. Surprisingly, the concomitant use of goserelin and adjuvant chemotherapy improved disease-free survival (HR 0.47, P=0.04) and overall survival (HR 0.45, P=0.05) versus chemotherapy alone in ER negative premenopausal early BC patients in POEMS study, which was initially aimed to improve the success pregnant rate (N Engl J Med 2015 372;923). Endocrine therapy is theoretically antagonist to chemotherapy therapy when concomitantly use. In another report analyzed the outcome of both pre- and postmenopausal women who entered two randomized trials (Gruppo Oncologico Nord-Ovest-Mammella Intergruppo studies) on adjuvant chemotherapy and received either concomitant or sequential hormonal therapy. The result showed a decreasing trend (P = 0.015) in hazard ratio of death with increasing age was observed, indicating that concomitant therapy is more effective than sequential therapy in young patients (Annals of Oncology 2008;19(2):299-307). These results support the hypothesis that, E2 suppression/ER inhibition therapy may modulate immune microenvironment, thereby enhancing the chemotherapy induced immunogenic death effect. The investigators hypothesized that, estrogen level reduction by ovarian function suppression can modulate immune microenvironment, thereby augmenting adjuvant chemotherapy efficacy, regardless of the estrogen receptor (ER) status of cancer cell. Therefore, the investigators plan to test this hypothesis in real clinical model, with standard clinical recommended treatment doses. The study is designed to evaluate whether the GnRH agonist can provide the therapeutic benefit for premenopausal TNBC patients via modulating immune microenvironment. Premenopausal TNBC patients will receive GnRH agonist and neoadjuvant chemotherapy, and the efficacy and immune microenvironment change of co-administration arm will be measured and compared with chemotherapy alone control arm.

Interventions

Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mgDrug

Arms2

Experimental
Arm A
After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The protocol-defined chemotherapy will be given 7 to 14 days after GnRH agonist injection. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion. * Anthracycline-cyclophosphamide combination or Anthracycline-cyclophosphamide combination, dose-dense schedule * Taxane (docetaxel or paclitaxel) ± optional platinum (Use of platinum or not will be stratified.) * Optional pembrolizumab(Use of pembrolizumab or not will be stratified.)
No intervention
Arm B
* Anthracycline-cyclophosphamide combination or Anthracycline-cyclophosphamide combination, dose-dense schedule * Taxane (docetaxel or paclitaxel) ± optional platinum (Use of platinum or not will be stratified.) * Optional pembrolizumab(Use of pembrolizumab or not will be stratified.)

Primary outcomes1

Outcomes the sponsor listed as primary.

Pathological complete response rate
Time frame · During surgery
Registry description
No invasive residual in breast or nodes; non-invasive breast residuals allowed

Secondary outcomes(11)

Event free survival
Time frame · From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Registry description
To compare the event-free survival (EFS) assessed by investigator in ITT population after neoadjuvant chemotherapy with/without ovary suppression
Quality of life from patient-report outcome
Time frame · At Screening phase, at Treatment 1 cycle 4 day 1 ( each cycle is 14 days or 21 days) , at Treatment 2 cycle 4 day 1 (each cycle is 14 days or 21 days), through study completion, an average of 5 years
Registry description
Quality of life will be assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 , the minimum values is : 30 , the maximum values is : 126, the higher scores mean a worse outcome
Estradiol
Time frame · At Screening phase, at Treatment 1 cycle 1 day 1, at Treatment 1 cycle 3 day 1, at Treatment 2 cycle 1 day 1, at Treatment 2 cycle 3 day 1, during surgery, through study completion, an average of 5 years
Registry description
Estradiol (E2) pg/mL
Follicle stimulating hormone
Time frame · At Screening phase, at Treatment 1 cycle 1 day 1, at Treatment 1 cycle 3 day 1, at Treatment 2 cycle 1 day 1, at Treatment 2 cycle 3 day 1, during surgery, through study completion, an average of 5 years
Registry description
Follicle stimulating hormone (FSH) mIU/mL
Luteinizing hormone
Time frame · At Screening phase, at Treatment 1 cycle 1 day 1, at Treatment 1 cycle 3 day 1, at Treatment 2 cycle 1 day 1, at Treatment 2 cycle 3 day 1, during surgery, through study completion, an average of 5 years
Registry description
Luteinizing hormone (LH) mIU/mL
Tumor microenvironment changes after neoadjuvant chemotherapy with/without ovarian suppression
Time frame · At Screening phase, at Treatment 1 cycle 1 day 1 ( each cycle is 14 days or 21 days), at Treatment 2 cycle 1 day 1 ( each cycle is 14 days or 21 days), through study completion, an average of 5 years
Registry description
To evaluate the tumor-infiltrating lymphocytes (TIL)
Pathological complete response by tumor infiltrating lymphocyte
Time frame · During surgery
Registry description
To evaluate the rate of pCR (ypT0/Tis ypN0) as assessed by the local pathologist at the time of definitive surgery in individuals with TIL(+) or TIL(-) tumors.
Residual cancer burden
Time frame · During surgery
Registry description
To evaluate Residual Cancer Burden (RCB) as assessed by the local pathologist at the time of definitive surgery
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame · up to 32 weeks
Registry description
To determine the safety and tolerability of ovarian function suppression in combination with neoadjuvant chemotherapy in locally advanced TNBC subjects
Breast cancer quality of life from patient-report outcome
Time frame · At Screening phase, at Treatment 1 cycle 4 day 1 ( each cycle is 14 days or 21 days) , at Treatment 2 cycle 4 day 1 ( each cycle is 14 days or 21 days), through study completion, an average of 5 years
Registry description
Breast cancer quality of life will be assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire BR23 , the minimum values is : 22 , the maximum values is : 92, the higher scores mean a worse outcome
Event free survival by tumor infiltrating lymphocyte
Time frame · From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.
Registry description
To evaluate the event free survival by investigator in individuals with TIL(+) or TIL(-) tumors.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies3

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2015

4 results

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore et al. 2015The New England journal of medicinecited by 368

PMID 25738668PMC4405231DOI 10.1056/nejmoa1413204PUB-25738668

Rights unknown4 results

Source link See results (4)

Indexing hint: Randomized controlled trial · 2014

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani et al. 2014The New England journal of medicinecited by 530

PMID 24881463PMC4175521DOI 10.1056/nejmoa1404037PUB-24881463

Rights unknown

Source link

More studies

1 study on this page

Indexing hint: Clinical trial · 1996

Phase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancer.

Garcia-Giralt et al. 1996American journal of clinical oncologycited by 5

PMID 8823473DOI 10.1097/00000421-199610000-00006PUB-08823473

Full text at the publisher

Publisher page

Eligibility

Who could join, as posted.

Sex: Female
Age: from 18 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Female patients aged ≥ 18 years at screening; Must be premenopausal according to serum E2, FSH level. 3. Histological confirmed TNBC, as defined by the most recent ASCO/CAP guidelines. Hormone receptor-low/HER2 negative as defined by ER 1% to \<10% and/or PR 1% to \<10% on IHC staining; neither hormone receptor may be ≥ 10%; and HER2-negative (IHC 0+/1+, or IHC 2+ plus FISH negative) is allowed. 4. Have previously untreated locally advanced non-metastatic (M0) TNBC and hormone receptor-low/HER2-negative defined as the following combined primary tumor (T) and regional lymph node (N) staging per current AJCC staging criteria for breast cancer staging criteria as assessed by the investigator based on radiological and/or clinical assessment: T1c, N0-N2; or T2, N0-N2; or T3, N0-N2; or T4a-d, N0-N2. 5. Agree to receive core needle biopsy for translational research. 6. ECOG 0-1. 7. Patients must have adequate organ and marrow reserve measured within 14 days prior to randomization as defined below: * Hemoglobin ≥ 9.0 g/dL; * Absolute neutrophil count ≥ 1,500 /μL; * Platelets ≥ 100,000/μL; * Total bilirubin ≤1.5 x upper normal limit; * AST(SGOT)/ALT(SGPT) ≤ 2.5 x upper normal limit; * Serum creatinine ≤ 1.5mg/dL or creatinine clearance ≧50ml/min; * aPTT \< 1.5 x upper normal limit (unless on therapeutic anti-coagulation); 8. Plan to receive breast cancer surgery. 9. Must have a negative pregnancy test obtained within 3 days before starting therapy. Patients must not be breastfeeding. 10. Patients must use effective contraception prior to study entry and for the duration of study participation, and for 6 months after the completion of therapy. 11. Patients (or a surrogate) must be able to comply with study procedures and to give signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the clinical study protocol (CSP). The patients (or a surrogate) must be able to provide of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses. Exclusion criteria Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the Investigator, in order to ensure that the study population will be representative of all eligible patients. 1. Patients have received any prior therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or hormone therapy) for breast cancer. 2. Evidence of systemic metastasis. 3. Pregnancy or lactation. 4. Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. 5. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs, with exception of hydroxychloroquine (Plaquenil®)) in subjects planning for pembrolizumab use. 6. Has a diagnosis of immunodeficiency or is receiving high dose of systemic steroid therapy. Patients with minor medical disease condition (i.e. mild asthma) requiring prednisolone equal to or less than 20 mg/day or the equivalent may be allowed. 7. Has an active systemic bacterial, viral or fungal infection requiring systemic therapy. 8. Psychiatric illness or social situation that would preclude study compliance. 9. Serious non-healing wound, ulcer, or bone fracture. Except for breast cancer related non-healing wound or ulcer. 10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrolment. 11. History of allergic reaction to compounds of similar chemical composition to the study drugs. 12. Any of the following conditions or treatments that may impact the safety of the patient: * History of, or current, significant cardiac disease including cardiac failure (NYHA functional class II-IV), myocardial infarction (within 6 months), unstable angina (within 6 months), transient ischemic attack (within 6 months), stroke, cardiac arrhythmias requiring treatment or uncontrolled arterial hypertension * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker on screening electrocardiogram (ECG) * History of or active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis * Severe hepatic impairment (Child-Pugh class C) * Any medically unstable condition as determined by the Investigator 13. Patients unable or unwilling to undergo serial breast tumor biopsy. 14. History of hypersensitivity to any of the study drugs.

PepBank is a research reference. Talk to a doctor before you use any peptide.